Ignite Creation Date:
2025-12-24 @ 1:07 PM
Ignite Modification Date:
2025-12-31 @ 1:44 PM
Study NCT ID:
NCT03784261
Status:
UNKNOWN
Last Update Posted:
2021-09-21
First Post:
2018-12-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Usefulness of Non TNF Usage in RA Patients
Sponsor:
Shinshu University
Organization:
Study Overview
Official Title:
Usefulness of Non TNF Usage in Rheumatoid Arthritis Patients
Status:
UNKNOWN
Status Verified Date:
2021-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:
1. Sarilumab treatment for 12 months
2. Tocilizmab treatment for 12 months
3. Abatacept treatment for 12 months
1. Sarilumab treatment for 12 months
2. Tocilizmab treatment for 12 months
3. Abatacept treatment for 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: